NEWS & EVENTS

March 7th 2022

EU SolidAct continues, randomising only immunocompromised patients in the baricitinib trial 

EU SolidAct continues, randomising only immunocompromised patients in the baricitinib trial  Based on recent results from the Recovery trial showing a mortality benefit for baricitinib in severe COVID-19, EU SolidAct has decided to stop inclusion of immunocompetent participants to the baricitinib trial. However, as the safety and benefit of immunomodulators including baricitinib is still not [...]
Read more
March 2nd 2022

remdesivir has a significant antiviral activity, reducing the amount of viral particles released by infected cells

An article published on 2 March in The Journal of Antimicrobial Chemotherapy, shows the effect of remdesivir on viral dynamics in COVID-19 hospitalized patients.  The use of remdesivir has been associated to contradictory virological and clinical results in the past months. Here, we analyzed its effect on viral dynamics in the DisCoVeRy trial, where 665 [...]
Read more
January 27th 2022

BerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients

Bergen, Norway and Oslo, Norway 27 January 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs and Oslo University Hospital announced today the execution of a collaborative agreement to study the BerGenBio AXL inhibitor bemcentinib, in hospitalised COVID-19 patients.   The EU-SolidAct trial - European [...]
Read more
September 24th 2021

Remdesivir Ineffective in Patients Hospitalized With COVID-19 and the DisCoVeRy Trial Continues with a New Antiviral

The Discovery clinical trial was initially launched in France by Inserm in March 2020, to evaluate several possible treatments for COVID-19. Its European expansion was made possible by the EU-RESPONSE[1] project, funded by Europe. Interim analysis of the trial data had led to the recommendation to suspend the recruitment of remdesivir group patients for futility [...]
Read more
June 28th 2021

Launch of European Covid-19 trials coordination module website

Launch of European Covid-19 trials coordination module website. The coordination module of the EU-funded projects RECOVER1 and EU-RESPONSE2 has launched its website https://covid19trials.eu/en. It centralises information for academics and industry on access to the three large Pan-European adaptive platform trials currently underway: DisCoVeRy, EU-SolidAct & REMAP-CAP. A coordinated Pan-European approach is essential for tackling the [...]
Read more
May 28th 2021

EU SolidAct – a pan-European platform for pandemic research and preparedness

EU SolidAct - a pan-European platform for pandemic research and preparedness There is an urgent need for rapid and coordinated investigation of new candidate drugs during pandemics. EU-SolidAct is an Adaptive Platform Trial developed to evaluate drug interventions in hospitalized patients with COVID-19 and to facilitate a joint European response to future pandemics. The first [...]
Read more
April 29th 2021

Inserm and AstraZeneca join forces to test the efficacy of monoclonal antibody combination AZD7442 on Covid-19 in the European DisCoVeRy trial

April 29, 2021 – A long-acting antibody (LAAB) combination developed by AstraZeneca is to be evaluated in DisCoVeRy, the Inserm-coordinated European trial aimed at finding a treatment for COVID-19. It is planned to enroll 1240 patients across Europe in this Phase III clinical trial. With its wealth of experience in the domain of targeted therapies [...]
Read more
October 20th 2020

Launch of the EU-RESPONSE project

The EU-RESPONSE Kick-off meeting took place on October 20th 2020 via videoconference. This meeting gathered the whole EU-RESPONSE consortium to present and discuss the planned work programme with the participation of European Commission representatives and external invitees.
Read more
July 1st 2020

DisCoVeRy trial in practice

The DisCoVeRy clinical trial is an adaptive, randomized, open-label clinical trial, add-on of the Solidarity trial, that aims to evaluate the safety and efficacy of four antiviral therapeutic strategies as compared with standard of care. Patients are hospitalized in conventional departments or intensive care units both from academic or non-academic hospitals throughout Europe with COVID-19 [...]
Read more